i3 Health

i3 Health


Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy

STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to treatment dose reductions or discontinuation in severe cases. In one study of 123 patients receiving taxane therapy for breast cancer, 17% required dose reductions because of CIPN (Bhatnagar et al, 2014). Whereas in some patients the symptoms of...
i3 Health

Bringing Precision Medicine to Cholangiocarcinoma With Mitesh Borad, MD

STATEMENT OF NEED With an estimated incidence of 8,000 new cases per year, cholangiocarcinoma is a rare and aggressive tumor type that accounts for only 3% of all gastrointestinal cancers. Outcomes are poor, with 5-year survival rates ranging from 24% to as low as 2%. In this episode of Oncology Data Advisor, Mitesh J. Borad, MD, Associate Professor of Medicine and Director of the Liver and B...
i3 Health

Burnout-Prevention and Coping Tactics for Oncologists

This episode of Oncology Data Advisor with Daniel McFarland, DO, Northwell Health Lenox Hill Hospital, focuses on physician burnout, work-related stress, and the effects, including depression and exhaustion, that many physicians are facing from the challenges of the COVID-19 pandemic. Listen now to learn new strategies to combat these challenges! STATEMENT OF NEED Physician burnout and wor...
i3 Health

Clinical Updates and Expert Guidance in Prostate Cancer

STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from cast...
i3 Health

Defining Personalized Care Plans in Metastatic Colorectal Cancer

STATEMENT OF NEED Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is s...
i3 Health

Expert Guidance on New Advances in Renal Cell Carcinoma

STATEMENT OF NEED Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation a...
i3 Health

Exploring Novel Treatment Strategies for Metastatic Colorectal Cancer

STATEMENT OF NEED Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is s...
i3 Health

Immune Thrombocytopenia: Evolving Treatment Paradigms and Patient-Centered Care

STATEMENT OF NEED Immune thrombocytopenia is an acquired immune-mediated disorder defined as a peripheral blood platelet count
i3 Health

Keeping Pace With Evolving Treatment Paradigms in Advanced Renal Cell Carcinoma: The Nurse’s View

STATEMENT OF NEED Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation a...
i3 Health

Management of Cancer Pain: Current Guidelines

STATEMENT OF NEED Cancer patients often experience a range of symptoms that negatively impact their quality of life. Among the most debilitating is pain. Despite efforts to increase awareness, cancer pain is still underdiagnosed and undertreated and patients do not obtain complete relief. Although numerous management guidelines for cancer pain have been developed, most health care practitione...
i3 Health

Management of Venous Thromboembolism in Ambulatory Patients With Cancer

STATEMENT OF NEED Venous thromboembolism (VTE) is a common and potentially life-threatening complication in patients with cancer. There are two main types of VTE: deep vein thrombosis (DVT) and pulmonary embolus (PE), which can cause right heart failure, cardiopulmonary collapse, and death (Ozaki & Bartholomew, 2012). Patients who develop PE require hospitalization, increased oxygen requireme...
i3 Health

Management of Venous Thromboembolism in Hospitalized Patients With Cancer

STATEMENT OF NEED Venous thromboembolism (VTE), which consists primarily of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a life-threatening complication in hospitalized patients with cancer, and is associated with a 2- to 6-fold increase in likelihood of death (NCCN, 2016). The mainstay of treatment is anticoagulation; however, since cancer patients with VTE have higher rates of...
i3 Health

Metastatic Breast Cancer: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

STATEMENT OF NEED Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population (ACS, 2019). Although many women benefit from regular screening as well as earlier and improved treatment, approximately 6% present with metastatic disease, and up to 30% with no initial lymph node involvement ev...
i3 Health

Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

STATEMENT OF NEED Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of c...
i3 Health

New Data and Clinical Perspectives on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States. An estimated 191,930 new cases are diagnosed annually, and 33,330 people die from the disease (ACS, 2020). Most patients with metastatic hormone-sensitive prostate cancer (HSPC) present with relapse after local treatment, while approximately 5% of all prostate cancer patients present with de no...
i3 Health

Novel Treatment Options in Mantle Cell Lymphoma With Gilles Salles, MD, PhD

An aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncology Data Advisor, Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, joins...
i3 Health

Nursing Management of Bone Health in Patients With Cancer

STATEMENT OF NEED Many tumors, such as prostate, breast, lung, and multiple myeloma, affect bone health. Once cancer spreads to the skeletal system, the risk for pain, fractures, hypercalcemia, and nerve compression increases considerably. Several studies have shown that the use of antiresorptive agents such as bisphosphonates and monoclonal antibodies can reduce the morbidity of skeletal com...
i3 Health

Oncology Nursing Showdown: Advanced Non-Hodgkin Lymphoma Edition

STATEMENT OF NEED An estimated 77,240 new cases of non-Hodgkin lymphoma (NHL) are diagnosed each year in the United States. A number of disease subtypes exist, including follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). An indolent, difficult-to-treat B-cell malignancy, FL comprises approximately 22% of all cases of NHL. Currently, allogeneic hematopoietic stem cell transplant...
i3 Health

Optimizing Patient Outcomes in Pancreatic Cancer With Al B. Benson, MD, FACP, FASCO

With 5-year survival rates of only 37% for local disease, 12% for regional disease, and 3% for distant disease, pancreatic cancer is one of the most aggressive forms of cancer and one of the most challenging to treat. Despite the development of novel treatment approaches, therapeutic options remain limited. In this episode of Oncology Data Advisor, Al B. Benson, MD, Professor of Medicine at Nort...
i3 Health

Optimizing the Management of Moderate-to-Severe Atopic Dermatitis in Adult Patients

STATEMENT OF NEED Atopic dermatitis is a severe form of eczema pathologically characterized by skin barrier disruption mediated by a type 2 helper T-cell immune response. The incidence of atopic dermatitis is high, estimated to be approximately 15% to 20% in children and 1% to 3% in adults worldwide (Avena-Woods, 2017). In addition to the hallmark clinical symptoms of eczema and intense pruri...
i3 Health

Prevention of Medical Errors in Nursing Practice

STATEMENT OF NEED Medical errors are among the most common health-threatening mistakes that affect patient care, accounting for as many as 250,000 deaths per year in the United States (Makary & Daniel, 2016). Medical errors are considered a global problem, complicating a patient’s primary condition for which they needed medical attention. These errors can lead to adverse outcomes such as incr...
i3 Health

Treatment Advances in Gastrointestinal Stromal Tumor With Shreyaskumar Patel, MD

STATEMENT OF NEED The fact that gastrointestinal stromal tumor (GIST) is a rare tumor type, with an estimated incidence of 3,300 to 6,000 new cases per year in the United States, can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest therapeutic developments. Treatment for GIST has seen exciting progress this year, with two new FD...
i3 Health

Understanding Evolving Therapeutic Strategies for Graft-Versus-Host Disease (Module 1: Diagnosis, Risk Assessment, and Staging; Module 2: Current and Emerging Therapeutic Strategies)

STATEMENT OF NEED Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients and accounting for 15% of posttransplant mortality. Acute GVHD is the second-leading cause of transplant-related mortality and typically targets the skin, gastrointestinal tract, and liver. Chronic GVHD often presents dur...
i3 Health

Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma

STATEMENT OF NEED Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 2,488 cases are diagnosed in the United States annually (Paulson et al, 2018). The incidence of MCC has risen rapidly during the past few decades, which has been attributed in part to people living longer with...
i3 Health

Update on Therapeutic Advances in T-Cell Lymphoma

Join Steven M. Horwitz, MD, Member and Attending Physician at Memorial Sloan Kettering Cancer Center, as he discusses guideline recommendations for differential diagnosis of TCL, novel treatment strategies, and best practices for managing side effects in this case-based CME/NCPD activity! STATEMENT OF NEED Each year, 74,240 new cases of non-Hodgkin lymphoma are diagnosed and 19,940 people...
i3 Health

Video Viewpoint Strategy Session: Expert Guidance on the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer

STATEMENT OF NEED An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 84% of cases are classified as non-small cell. Most patients are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management (ACS, 2020). Although 70% of patients receiving fi...
i3 Health

Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes

STATEMENT OF NEED Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usu...
i3 Health

Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Advanced Soft Tissue Sarcoma

STATEMENT OF NEED Soft tissue sarcomas are a heterogeneous group of malignancies that arise primarily from the mesodermal tissues of the extremities, trunk and retroperitoneum, and head and neck. An estimated 13,130 new cases are diagnosed in the United States annually and 5,350 people die of the disease. Surgical resection is the mainstay of treatment for localized soft tissue sarcoma, with ...
i3 Health

Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Metastatic Breast Cancer

STATEMENT OF NEED Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population (ACS, 2020). Although many women benefit from regular screening as well as earlier and improved treatment, approximately 6% present with metastatic disease, and up to 30% with no initial lymph node involvement ev...
i3 Health

Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Relapsed/Refractory Follicular Lymphoma

STATEMENT OF NEED Of the estimated 74,200 new cases of non-Hodgkin lymphoma each year in the United States, approximately 22% are FL, an indolent, difficult-to-treat B-cell malignancy (ACS, 2019; NCCN, 2019). Most patients are diagnosed at an average age of 63 years (NCI, 2019). Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and ...
i3 Health

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map